SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Pastimes : Raymond L. Dirks Internet Research Tribunal Thread -- Ignore unavailable to you. Want to Upgrade?


To: SEC-ond-chance who wrote (325)12/13/2003 4:09:01 PM
From: StockDung  Respond to of 544
 
scan.cch.com



To: SEC-ond-chance who wrote (325)12/13/2003 5:14:11 PM
From: StockDung  Respond to of 544
 
Insider trading at New Tel

Thursday 11 December 2003, 23:51:45
Australia
Written by Margaret Dennis

The corporate regulator has been criticised for not taking any notice of an admission of insider trading at collapsed telco New Tel.

A former employee has admitted insider trading as well as their willingness to others involved in the scam, but it appears that no-one is keen to know about it.

In an effort to be heard, the employee took documents indicating dubious trading to The Australian.

Investigators from ASIC (Australian Securities and Investment Commission) dont seem to be interested in what the employee has to say and have made no contact with the employee since she was forced to cancel a scheduled meeting with them in June.

"They have my phone number but have never called me back. I had to cancel the meeting because of work but you would think they might be able to arrange a meeting out of work hours," the employee said.

She is quoted as saying that the trading of New Tel shares "was money for jam" and wanted to trade the information she holds for prosecution immunity.

She said that she had become frustrated with the fact that ASIC had failed in initiating prosecution over the companys controversial collapse.

The employee turned whistleblower said that she had made a small profit from a couple of trades (where she spent $5000 to gain a couple of thousand) she had made from tip-offs from a senior executive.

However, her broker informed her that she during the financial year, she had actually traded hundreds of thousands of dollars in the shares, and had made a profit of $36,000.

The employee claims never to have seen any of that money.

"My first thought was that I would have to declare that to the taxman but I didnt have the money," she said. "My accountant found it hard to believe but I could prove I had never received that sum of money."

The employee said she believed the trades in her name were on behalf of other executives at New Tel.

This former employee is not the only one to have come forward and ASIC actually interviewed many of them, but still not a word from ASIC about the company collapse.

And they sentenced Renee Rivkin for 9 months of weekend detention for the same crime with a financial gain of only a few hundred dollars.

Justice is said to be for all - but just who is included in that all seems to be highly selective, in Australia at least.

Source: Australian IT



To: SEC-ond-chance who wrote (325)12/13/2003 8:21:33 PM
From: StockDung  Respond to of 544
 
OTC JOURNAL GRIFTERS PROMOTE RICHARD GEIST NEW BOOK

"Dick has written a new book entitled Investor Therapy. The cover reads: A Psychologist & Investing Guru Tells You How To Out-Psych Wall St."

Subj: Confessions of a Serial Microcap Investor
Date: 12/13/2003 7:17:16 PM Eastern Standard Time
From: bounce-otcjournal-200797@lyris.otcjournal.com
Reply-to: info@otcjournal.com
To: XXXXXXXXXXXXXXXXXXXXXXX
Sent from the Internet (Details)

If you are reading this message in plaintext or if you have an AOL address you must click on this link: otcjournal.com and wait for a web page to automatically open up to properly read this newsletter.

December 13, 2003
Volume VI, Issue 125

Email : info@otcjournal.com
URL : otcjournal.com
To OTC Journal Members:


Don't Forget to Become a Preferred Member
Don't forget to subscribe to the free preferred member list, simply click here. You will receive an email confirmation. Then simply hit REPLY and SEND. You will be included in the Preferred Members list. You only need to do this once.
Or, to subscribe by email, send a blank email to otcjournal-preferred-subscribe@lyris.otcjournal.com.
If there is any problem, you can always go to otcjournal.com and submit your email address.

For those of you who are wondering; it's free and we have no plans at this time to charge preferred membership.


Confessions of a Serial Microcap Investor


I admit it. I am a serial microcap investor. I love investing in small stocks, and my portfolio has the wins and losses to prove it. The other day, one of my brokers laughed at me when he confirmed a trade. I called him to buy a three letter symbol of a small mining company trading on the obsure Canadian Venture Exchange. He said: "Just to confirm- you bought 30,000 shares of XYZ corp (I won't disclose the name)". I replied- Thanks for letting me know- I was wondering what the actual name of the company was. He laughed. Of course, it was a "hot tip" from a friend. I'll roll the dice on just about anything. However, I know the amount of money I am comfortable investing in that type of idea, and exactly how much risk I am willing to take. If the trades goes against me, I will take my loss.

I'll stop buying microcap stocks when I'm dead. I know many of you reading this are also microcap lovers. Microcaps are not for everybody. Are you a "self aware" microcap investor. Do you understand the psychology of microcap investing. Are you willing to accept the inevitable losers and can you handle it?



Dr. Richard Geist, Harvard Ph.D. in psychology, and probably the foremost expert in the world on the psychology of microcap investing is a friend and contributing editor to the OTC Journal. His section on the site has seven excellent articles. Invest a few minutes of your time to read his contributions.

Dick has written a new book entitled Investor Therapy. The cover reads: A Psychologist & Investing Guru Tells You How To Out-Psych Wall St.

Today's edition contains another outstanding contribution from Dick. It is an excerpt from his book entitled "Why Microcaps Outperform". Please take the time to read this article. You will find it fascinating.

Dick's new book would make an excellent edition to your library, or an excellent Christmas Present for one of your serial microcap investing friends. Here's the article. Afterwords, I will tell you how to buy the book at a big discount:


Why Micro-Caps Outperform
Dr. Richard Geist
John Cole, one of our most prolific observers of the natural world, once described the flight of the rarely seen frigate bird I a way that reminds me of many who invest primarily in small and micro-cap stocks:

These birds are designed for flight, nor perching; for gliding, not walking, running or scratching in the ground like wild turkeys. The air’s upper reaches are where the frigate bird lives most of its life, soaring, riding the thermals like a skier on invisible, airy slopes, finding hills in the sky, dipping along the rim of a great cumulus, then soaring suddenly higher on a windward thrust those of us watching from below will never feel, see or comprehend.

Like the frigate bird, small- and micro-cap investors are not made for perching or walking, or even gliding. We are searching for those potential once-in-a-lifetime opportunities—the ten baggers, as Peter Lynch coined them—that will make life a bit easier if we are right about their prospects for soaring suddenly higher on a windward thrust of the thermals. We know the well-established companies, however, successful, will trade below those windward thrusts, their market values likely to continue appreciating year after year at a slow but healthy enough rate to assure comfortable wealth by the time we retire. Yet for the entrepreneurial investors, there is something missing in this traditional path. My interviews with micro-cap investors suggests that what makes individuals buy and sell micro-cap stocks often involves more than just monetary wealth. Part of the allure involves the process of discovering and participating in exciting business opportunities, a process that can stimulate our imagination and augment the psychological cement that holds our sense of self together.

Investing in micro-cap stocks is not for everyone. It means taking losses in speculative stocks or small companies that never make it, while maintaining our convictions that creative research and intuition will pay off with enough large winners to far outweigh the losers. It requires the discipline to do more research than most are willing to perform, the capacity for assuming higher risk than most are willing to take, the balance to experience grandiosity yet keep it well controlled, the patience to endure the long time frame often required for innovative products and services to catch on, the confidence to eschew the investment community’s fixation on short term results and quarterly statistics, and a knack for viewing the world in a way that is both highly focused and expansive.

Having said that, however, there are a number of reasons why small companies out-perform large firms by significant percentages over the long term — by about 2.5% per year according to the Chicago research bureau Ibbotson Associates. 2.5% may seem like a minimal amount, but consider the following numbers. If you invested $10,000 that compounded at 10% for 20 years, you would end up with $67,275. If you invested $10,000 that compounded at 12.5% for 20 years, you would accumulate $105,451. That’s a large difference.

The Elimination of Group Think. The first reason that small caps outperform is that developing enterprises need to be innovative and nimble, and that tends to free them from the constraints of group think or herd mentality. Large institutions shy away from smaller stocks because they literally have too much money to invest and it is more efficient to spread their funds among fewer higher priced issues than thousands of lower priced ones. In addition it is impossible for institutions to buy or sell large blocks of small cap stocks without upsetting their market prices.

While the elimination of institutional participation levels the playing field for us individual investors and gives us a better opportunity for substantial profits, it also means we have to act completely independently of the “conventional wisdom” of the Street. As Bernard Baruch once said, most information reaches Wall Street through a “curtain of human emotions.” With little institutional guidance, the small cap investor is left alone to distinguish fact from fiction. Functioning in a virtual vacuum, our grandiose fantasies sometimes need only the slight stimulus of a friendly “can’t lose” tip to play havoc with rational decision making. Thus the small cap investor must constantly guard against rumors and tips, and the fantasies stimulated by working in a more isolated environment.

Pricing Inefficiencies. The second reason small stocks outperform is the dearth of research coverage for emerging companies. Since institutions are generally disinclined to buy small cap stocks, most institutional analysts don’t conduct extensive research on their issuers. Instead of the usual 10-15 analysts reports, we are lucky to find 1 or 2, and these are usually from the company’s investment bankers, who tend to be small outfits themselves and often have their own public relations agenda. Without the typical consensus on earnings estimates, the potential for pricing inefficiencies (i.e. incorrect valuations) is greater, offering the individual investor a competitive edge.

Capitalizing on these pricing inefficiencies, however, exacts a psychological toll on the investor. Exceptional opportunities, by definition, are rare, and uncovering them requires thorough financial analysis and sound understanding of the company, the industry, and the economic factors effecting the industry and the company’s products or services. Doing the job the right way demands enormous time and energy, commodities that are usually in short supply when preoccupied with family and a full time job outside the investment field. So there is a tendency to create our own ostensibly rational assessment of a company based on fantasies woven from incomplete facts and inordinate expectations.

Lower Liquidity, Higher Rewards. The third reason for out performance is that small companies often have fewer shares outstanding and fewer buyers and sellers for their stock. In other words they are more thinly traded and not as liquid as large stocks. Combining this small float with a usually low price, individual investors can often gain much more leverage in small stocks. It’s much easier for a $2 stock to increase 300% than it is for a $60 stock to increase 300% in the same time frame. Because it can be harder to convert your holdings to cash at a moment’s notice, investors demand a higher reward for the increased liquidity risk. Higher potential rewards, however, mean increased psychological pressure to tolerate uncertainty: the uncertainty of exiting stocks in the face of a sudden correction or bear market; the sense of doubt from realizing you cannot have all the information necessary for informed decisions; and the uncertainty that you have made a correct decision in purchasing a stock despite a temporary pull back in its trading price. The more prolonged an investor’s uncertainty in the context of lone decision-making, the greater the likelihood of acting irrationally—selling at the bottom or chasing stocks and buying at the top.

Volatility. Finally Small stocks possess more “company risk” than large caps. For example, they often don’t have the financial strength to survive one poor year, whereas a Pepsico, IBM or Microsoft merely restructures and continues its corporate life after adjusting to bad times. Volatility in this sense means that small companies have the capacity to disintegrate quickly. The small caps of course also have more volatility in the market sense, and their stock can move precipitously and rapidly.

The psychological pressures inherent in the volatility of small caps can compel investors, mistakenly, to make snap decisions more akin to stock and commodity traders than to long-term investors. Quickly falling prices following a poor quarter or other disappointing development elicit an urgency to sell at what may well turn out to be rock bottom levels. Rapidly rising prices can elicit a craving for short term profit taking, which calms the nerves but often at the expense of enormous up-side potential. Because most brokers do not follow the small cap arena carefully if they follow it at all, they frequently join in the panic, encouraging their customers to sell at just the wrong moment. Unanalyzed impatience is perhaps the most insidious psychological danger for the micro-cap investor. The small and micro-cap markets are not for you if your self esteem depends on Mr. Market’s every day approval. But if you can tolerate market pressures and risks on a long-term rather than a short-term basis you will give yourself a fighting chance for meaning rewards.

Because micro-caps don’t usually have 5-10 years of financials to study, micro-cap investor must ask more qualitative questions about their prospective investments. Consider the following questions when investing in the micro-cap market.

1) Does your company have a visionary product or service that could change forever the way large groups of people, or whole cultures carry on their lives?
2) Will these products or services appeal to a niche market that are underserved by the existing products or services and that are willing to think in contrarian ways about new methodologies and tools?
3) Can management drive the company to success? In a micro cap company, no matter how good the product, a poor management team will inevitably lead to failure.
4) Is this the right time to buy? Ideally you want to buy at a point when nothing appears to be happening at the company, but your research has uncovered indications of positive developments.
5) Does the company have effective financial and public relations support? The most common pitfall for small companies is under-capitalization.
6) Can the company develop valuable strategic partnerships?
7) Finally, do you have the time to wait for small companies to become large companies? The average small company takes about 4-5 years to develop into a mature firm.






Here's a picture of the book cover. Order it, and read it. It's a training manual. It will make you a better microcap investor. Also, it would make an excellent Christmas present. The book is on sale at most book stores for $24.95. Amazon sells it for $17.47, a 30% discount. Get it today, and buy it for a friend.

Click Here to purchase Dick's book at Amazon. com. If all you serial microcap investors read this, I will have a highly educated audience.

--------------------------------------------------------------------------------




--------------------------------------------------------------------------------
Charts Provided Courtesy Of TradePortal.com

Disclaimer
The OTCjournal.com Newsletter is an independent electronic publication committed to providing our readers with factual information on selected publicly traded companies. All companies are chosen on the basis of certain financial analysis and other pertinent criteria with a view toward maximizing the upside potential for investors while minimizing the downside risk, whenever possible. Moreover, as detailed below, this publication accepts compensation from certain of the companies which it features. Likewise, this newsletter is owned by MarketByte, LLC. To the degrees enumerated herein, this newsletter should not be regarded as an independent publication.
Click Here to view our compensation on every company we have ever covered, or visit the following web address: otcjournal.com for our full profiles and otcjournal.com for Trading Alerts.

All statements and expressions are the sole opinions of the editors and are subject to change without notice. A profile, description, or other mention of a company in the newsletter is neither an offer nor solicitation to buy or sell any securities mentioned. While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein.

The editor, members of the editor's family, and/or entities with which they are affiliated, are forbidden by company policy to own, buy, sell or otherwise trade stock for their own benefit in the companies who appear in the publication unless specifically disclosed in the newsletter.

The profiles, critiques, and other editorial content of the OTCjournal.com may contain forward-looking statements relating to the expected capabilities of the companies mentioned herein.

THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK. THE INFORMATION FOUND IN THIS PROFILE IS PROTECTED BY THE COPYRIGHT LAWS OF THE UNITED STATES AND MAY NOT BE COPIED, OR REPRODUCED IN ANY WAY WITHOUT THE EXPRESSED, WRITTEN CONSENT OF THE EDITORS OF OTCjournal.com.

We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission ("SEC") at sec.govand the National Association of Securities Dealers ("NASD") at nasd.com. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at sec.gov. Disclaimer ID:4PvMONjL Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site.

--------------------------------------------------------------------------------


Unsubscribe Here



--------------------------------------------------------------------------------
You can unsubscribe from this list at any time by Clicking Here and HITTING SEND. If you are having difficulty removing yourself or wish to change your address please go to listserv.otcjournal.com@aol.com.



To: SEC-ond-chance who wrote (325)12/23/2003 5:34:16 PM
From: StockDung  Respond to of 544
 
Settled Litigation In December 1997, Raymond Dirks, Jessy Dirks, Robert Brisotti and David Morris filed an action in the Supreme Court for the State of New York, County of New York, against Eurotech, Ltd. for breach of contract, seeking injunctive relief, specific performance and monetary damages of nearly $5 million (the "Dirks Litigation"). The Dirks Litigation arises from an agreement between Eurotech and National Securities Corporation ("National") relating to financial advisory services to be performed by National Securities Corporation, a broker/dealer with which the plaintiffs were affiliated and of which Raymond Dirks Research was a division. Eurotech granted National a warrant certificate for 470,000 shares at $1.00 per share (as adjusted to reflect the June 1, 1996, four-to-one forward split of Eurotech common stock) as a retainer for general financial advisory services. In conjunction with the separation of the plaintiffs and Raymond Dirks Research from National Securities Corporation, National assigned a significant portion of the warrant certificate to the plaintiffs. This litigation was settled in October 1999, with an agreement to issue to the plaintiffs 181,784 shares of Eurotech common stock in twelve equal monthly installments valued at $456,278, in exchange for the cancellation of the warrants for 470,000 shares.

EUROTECH LTD
 Form: 10-K  Filing Date: 3/29/2001



To: SEC-ond-chance who wrote (325)1/3/2004 12:30:43 AM
From: StockDung  Respond to of 544
 
Highlighted Stock NEW TEL Ltd

Richard Geist's Strategic Investing
Richard Geist's Strategic Investing Home | Back Issues | Previous
Volume 6, Issue 7 Date: July 2000

Highlighted Stock
NEW TEL Ltd
Symbol: NWLL Nasdaq sm.cap
Symbol: NWL Australian stock Exch.
6/11/2000 price: $11 Buy current level
Shares Outstanding: 14 million ADRs
Address: 22 Hassler Rd.
Herdsman, WA 6017, Australia
Tel: 089.244.1166
New Tel is a young Australian based long distance and mobile telephone carrier that has focused on the niche Chinese community market in Australia. They launched operations in July 1999, providing national, international, and mobile telephony and data services between Australia and China. New Tel is one of six companies authorized to provide telecommunication services and equipment in Australia. They currently have 25,000 customers and expect that figure to double by year end.

Importantly for investors, this focus on China has led to an agreement with Xinhua Holdings Ltd to establish what could prove to be China's foremost Internet Service Provider (ISP) and Chinese/English language Portal.

Ground Breaking Internet Program in China
Business in China is based largely on trust, what the Chinese call "Guangxi." New Tel has developed a trusted relationship with the government, dating back to 1997 when they rolled out New Tel's telephony services via satellite gateway. Recently, as confirmation of this relationship, the Chinese embassy in Australia became a New Tel telephony customer.

Specifically, New Tel has a relationship with Xinhua Holdings Company, Ltd, the commercial arm of the Xinhua News Agency in China. Xinhua is the world's fourth largest news and wire service. In December 1999 New Tel announced that within six months, through a joint venture with Xinhua, it would acquire 18 web sites currently owned by the Chinese government in return for the issuance of 200 million shares (20 million ADRs) of New Tel stock. Depending on how the deal is structured, Xinhau will have an ownership of approximately 49%. If this deal happens, and we are basing our speculative recommendation of the stock on our belief that it will, New Tel will then become a leading Internet Service Provider and Internet Portal in China.

New Tel and Xinhua intend to work together with a number of government owned enterprises in China to accelerate the uptake of Internet access in China. The ISP business will leverage from existing ISPs, with strategic alliances with infrastructure providers enhancing the opportunities to reach a large portion of the Internet access market. The organizations that New Tel will work with include:

The Ministry of Information's (MII) E-information Center, which is responsible for the collection, analysis, and dissemination of information in the information technology market and government institutions.

China Statistical Information and Consultancy Center, a division of the State statistical bureau, which provides macro-statistical information on the national economy and social development.

The Information Center for Education Administration, an executive unit within the Ministry of National Education that maintains a website providing information relating to developments in education in China.

The China Economic Information Center, owned by the Ministry of Foreign Trade and Economic Cooperation. This authority maintains several websites providing information relating to foreign trade, export commodities, and technology companies in China.
The portal business will be closely related to the ISP business. New Tel plans to provide access to a broad range of Chinese content through its partnership with Xinhua and a number of China's most heavily visited websites that focus on information collection and dissemination across a range of industries.

Revenue Streams
New Tel's revenue sources will come from a variety of products and services: Internet access for corporations and consumers; website design and hosting services; management of corporate intranets and e-mail systems; and hosting of e-commerce applications. The portal business will establish recurring revenue streams through advertising, subscriptions for high value content, commissions from transactions originating from portal business, and e-commerce revenues from transactions occurring at portal businesses. The portal business will also provide access to a broad range of Chinese content, in both Chinese and English, and enable electronic commerce. Content will be available through New Tel's partnership with Xinhua and other ministry websites.

Competitive Advantage
There are more than 200 ISPs in China, with China Telecom having a dominant position. In addition, there are 1,100 e-commerce websites. There is also a growing number of content providers in China, which should help drive the growth of the Internet. Currently, according to the Ministry of Information, the most popular web sites in China are Sohu, Yahoo! and Sina.com. China.com functions primarily in the Taiwan and Hong Kong markets, whereas New Tel is focusing on mainland China.

The relationship with Xinhua enables the Company to obtain exclusive access to content from government agencies that will give it a solid competitive advantage in the market. In addition, New Tel's business model will have multiple revenue sources and two business arms that have a strong synergy. New Tel's strategic business partnerships, coupled with the advantage of starting up with a customer base and technology infrastructure already in place, strengthens its business model. Finally, and perhaps most importantly, New Tel is in bed with the Chinese government if the purchase of their 18 websites is achieved.

Industry
According to Interactive Audience Measurement Asia (iamasia) the number of Internet users in China has reached 12.3 million. It is currently estimated that Chinese Internet users are doubling every six months. The city with the highest Internet penetration is Beijing with 25%. Educational and corporate use remain the largest user base, followed by government and home users.

According to iamasia 5.7 million people use the Internet at home and 5.0 million use the Internet at work. A new report by International Data Corp. (IDC) projects that online advertising in Asia/Pacific will be in excess of US $1 billion by 2004, and is growing at a 76% compound annual growth rate from US$67 million in 1999. In a related area, Wen Hui Bao reported that e-commerce on the Chinese mainland rose 500% in 1999, from about US$8 million to over $40 million. Five percent of Internet users in China have made a purchase online. Computer hardware and software, books, and groceries are the top sellers. The government intends to have 80% of local governments online by the end of 2000 and 80% of Chinese companies online by the end of 2001.

Marketing
New Tel has appointed marketing consultants to promote the Company in China through a marketing campaign aimed at the country's twelve million Internet users. On the Telco side, New Tel plans to add local calling and Internet services to its product mix during the quarter, and the company will focus on creating solid brand positioning for products and services to new target markets, particularly ethnic communities and businesses.

Financials
Analysts are projecting $11.8 million in revenues for fiscal 2000 and $0.1 per share in earnings. For 2001 the figures jump to $50 million revenues and $0.09 per share. We are extremely skeptical of such projections because we believe that numbers will be a constantly changing target. Depending on how quickly deals are accomplished, such numbers could be much lower or higher. We will try to get a better handle on the numbers after (and if) the Xinhua deal is announced and a prospectus for raising the additional capital becomes public. Until that time, realize that you are investing in a concept--one that has huge potential because of the expected relationship with Xinhua. And that this potential is not yet reflected in New Tel's stock price. Earlier in the year the stock was at $50 per share, so we feel you are getting in at a significant discount to where most investors purchased the stock--in the $20s and $30s.

The closest international comparison to New Tel is China.com, a nasdaq listed company that just announced a $20 million revenue quarter and an operating loss of $18 million. It is capitalized at $2.2 billion. New Tel is currently capitalized at about $90 million ADRs. {Remember that for every 10 Australian shares, there is 1 US ADR (American Depository Receipt). The currency translation is $0.59 Australian to $1 U.S.}. New Tel has no debt and recently raised approximately US$35 million in a private placement to fund initial development of activities associated with its Internet project in China.

Risks
New Tel is currently a concept stock. They have a solid and growing Telcom business, but the real upside for investors is in the Internet business plan in China. If for any reason, the agreement with Xinhua is not consummated, you could lose your principal. So please be aware that this is a very high risk investment (with accompanying potential high rewards). New Tel must be able to raise over US$125 million to make the deal work, and there is no guarantee that this can be done. Doing business in China is always high risk in that companies are not in a position to control regulatory decisions within the Chinese government. It is important to note however, that Xinhau is represented on New Tel's Board of Directors. China must also remain committed to the development of the Internet in their country.

For speculative players, New Tel offers an unusual opportunity to enter the Chinese Internet market at a reasonable price. We think the Telecom business alone is worth $7 per share, so there is some protection on the downside. We would take a position in the $10-$12 range and then average up or down.



To: SEC-ond-chance who wrote (325)1/3/2004 1:01:02 AM
From: StockDung  Respond to of 544
 
Medi-Hut Co Richard Geist's Strategic Investing
Richard Geist's Strategic Investing Home | Back Issues | Previous
Volume 7, Issue 6 Date: June 2001

Highlighted Stocks
Medi-Hut Co., Inc.
Symbol: (MHUT) 5/15/01 Price $6.95
Shares Outstanding: 12.11 Million
Float: 8.9 million (approx)
Address: 1935 Swathmore Ave.
Lakewood, NJ 901060
Tel: 732-901-0606
www.medihutonline.com

Medi-Hut is in the business of wholesaling brand name drugs, their "Elite" brand and private label medical products and their "Tru-Choice" over the counter drugs. In addition, and the reason we are recommending the company now, is the recent introduction of their Elite Safety Syringe, the company's anti-stick safety syringe.

--------------------------------------------------------------------------------

Products
Name Brand Drugs are those drugs that are protected by patent or licensure. In September 1999 the Company began to wholesale Certia XT caps, Nubain, Terazosin ACL Caps, and Viagra. These name brand drugs represented 71.2% of their total revenues for fiscal 2000.

Medical Products include syringes, hot and cold packs, gauze bandages, adhesive bandages, condoms, and paper products, which accounted for about 22.2% of revenues for fiscal 2000.

Most importantly, however, Medi-Hut recently introduced their Elite Safety Syringe. Safety syringes are defined as those products that incorporate features designed to safely cover the sharp needle with minimal effort and minimize danger to the user by preventing accidental needlesticks.

--------------------------------------------------------------------------------

Two types of Safety Syringes
There are two types of anti-stick syringes: 1) active devices which demands that the user in some way make a physical movement to activate the device after the injection and prior to disposal; 2) passive devices, which activate automatically after injection and should be designed not to interfere with the normal injection procedure.

Medi-Hut's Elite Safety Syringe is a passive device that incorporates a transparent sleeve into which the needle will automatically retract after use. The Elite Safety Syringe had a 90% acceptance rating in its clinical evaluations. MHUT holds a patent for the syringe and has received a 510k Food and Drug Administration approval to market this syringe. Unlike many syringes now in the marketplace, the Elite Safety Syringe can be activated using a one hand technique.

--------------------------------------------------------------------------------

Production and Distribution
Production of the Elite Safety Syringe began in October 2000 in an ISO 9002 approved facility in Korea. In February the company received approval from the Korean Government for the formation of a joint venture with COA International Industries. Under its new foreign subsidiary, Medi-Hut International will have a 44% interest in COA's syringe production facility. Production is expected to reach between 6-7 million syringe pieces per month in the fourth quarter of fiscal 2001 (August). By January 2002 the Company expects to be producing about 18 million syringes per month. Sale of the product will occur primarily through distributors such as Darby Drug, one of the largest catalog distributors in the country.

--------------------------------------------------------------------------------

New OSHA Requirements
On November 6, 2000 Congress passed the Needlestick Safety and Prevention Act (HR 5178) directing OSHA to revise its bloodborne pathogens standard to identify and make use of effective and safer medical devices. That revision became effective April 18, 2001. The revision includes new requirements that require employers to take into account innovations in medical procedures and technological developments that reduce the risk of exposure to needlesticks, and document use of appropriate commercially available and effective safer devices. Employers must also solicit input from non managerial employees responsible for direct patient care regarding the selection of effective devices. HR 5178 makes it mandatory to use safety sharp medical devices in all 50 states.

--------------------------------------------------------------------------------

Industry
Health care workers, according to the American Nurses Association, suffer between 600,000 and one million injuries from conventional needles and sharps annually. These exposures can lead to hepatitis B, hepatitis C and Human immunodeficiency Virus (HIV). Currently only 15%-20% of hospitals use safety syringes. Within a year, experts expect 85% will have to use them. 18 states have ratified the federal law and 12 have it pending as of May 1, 2001. There are about 8 billion syringes used domestically and 20 billion used internationally per year. Currently all the players in the industry can't produce enough safety syringes to meet the demand.

--------------------------------------------------------------------------------

Competition
The safety syringe market is dominated by Becton Dickinson and Sherwood Medical. However, both of these companies manufacture an active device which requires two hands and activates manually after injection. The Elite Safety Syringe can be activated using a one hand technique and is priced lower than their competitors' products. Retractor Technologies, a Texas corporation, has entered the market place recently with a passive device similar to the Elite Safety Syringe. However, MHUT intends to price their product about 15% less than their competitor's syringe. Med Design (MEDC) also has a potentially passive syringe. That company is selling at about $17 per share and lost $0.30 per share last year. MHUT is selling at close to $7 per share and is expected to earn $0.10 per share this year. MHUT has recently applied for listing on the Small Cap Nasdaq, and, if all goes smoothly, we would expect that listing to occur by Labor Day.

--------------------------------------------------------------------------------

Financials (fiscal year ends October)
In the first quarter of fiscal 2001, ended January 31, 2001, the Company reported revenues of $2.2 million compared with $1.2 million in last year's first quarter. Net income was $104,796 or $0.007 per share versus a loss of $0.003 in last year's similar quarter. Current assets at the end of the quarter were $3.1 million, current liabilities were $2.5 million, yielding working capital $655,694 and a current ratio of 1.27. Cash and equivalents were $1 million (although this increased to $3 million after the quarter). Total Stockholders' Equity was $2.1 million, and there is no long term debt. Insiders own approximately 35.3% of the shares.

For fiscal 2001 we expect the company to report revenues of between $15-$18 million and earnings of $0.10 per share. For fiscal 2002, beginning in November 2001, we are expecting revenues of $55 million and earnings of $0.70 per share, assuming production ramps up according to the company's expectations. This is based on an estimated profit of about $0.10 per syringe pre tax and assuming that the company will bring in approximately $18 million from their non syringe businesses. Second quarter earings, which should be reported sometime in June, should probably show about $0.01 profit, but we expect a strong ramp up in the third and fourth quarters. Management anticipates that they may seek additional funding though future securities offerings to fund the growth of their syringe business.

In 2000 management completed its first acquisition, Vallar Consulting, which contributed to the $8.1 million sales recorded in fiscal 2000.

--------------------------------------------------------------------------------

Risks
There are four major risks of which you should be aware when considering an investment in Medi-Hut. First, the Company must finish their production facilities by mid summer if they are to produce product at the expect rate. Second, they must penetrate the difficult hospital market place. Third, Medi-Hut must be able to ramp up their growth quickly while maintaining their low cost structure. Fourth, MHUT must be able to maintain their competitive advantage. Currently we think they have a slight first mover advantage, but competition in the medical device industry is intense, and it will require superior marketing and flexibility to maintain their lead.

The stock has recently appreciated nearly 50% and we expect a slight pull back before it resumes its climb, so we suggest you try to buy under $7.00 per share.



To: SEC-ond-chance who wrote (325)2/5/2004 9:51:21 AM
From: StockDung  Respond to of 544
 
Sky Capital Holdings Ltd. ("Sky Capital" or the "Company") Offer for Subscription
Wednesday February 4, 2:53 am ET

LONDON, Feb. 4 /PRNewswire/ -- The Board of Directors of Sky Capital, the London and New York based Stockbrokers, is delighted to announce that Sky Capital has received applications in excess of 20 million pounds sterling ($36 million) in response to its UK and US Offer for Subscription of Series B New Convertible Preferred Shares (the "Offer").


Sky Capital has now brought the Offer to a close.

The funds from this Offer will considerably strengthen the Company's balance sheet and allow the Company to accelerate its growth strategy in New York, London and Florida where it is building a significant presence in the financial services sector.

Ross Mandell, Chief Executive Officer, commented, "I am extremely pleased with the response that we have received throughout the duration of this Offer. Investors in both the UK and the US have demonstrated great confidence in the future growth strategy of Sky Capital with their participation in one of the largest private placements ever undertaken in the UK.

"My fellow Directors and I look forward to the continued implementation of this growth strategy and to further enhancing our offering in the international financial services industry. I am confident that this, in turn, will be reflected in the increased value of Sky Capital for its shareholders."

--------------------------------------------------------------------------------
Source: Sky Capital Holdings Ltd.

Email this story



To: SEC-ond-chance who wrote (325)2/7/2004 8:45:55 AM
From: StockDung  Read Replies (1) | Respond to of 544
 
"Keynote by Dr. Richard Geist, noted author and President of The Institute of Psychology and Investing. Introduction by Larry Isen of the OTC Journal."

Webcast Alert: HyperDynamics Corp, NuTech Digital, The Project Group, And Spectrum Sciences & Software Presentations at OTC Journal's Emerging Growth Microcap Conference to be Webcast on Tuesday, February 10, 2004 At 12 pm ET
Conference, Co-sponsored by Trilogy Capital Partners, Focuses

On Emerging Growth Public Companies

LOS ANGELES, Feb. 7 /PRNewswire/ -- HyperDynamics (OTC Bulletin Board: HYPD), NuTech Digital (OTC Bulletin Board: NTDL), The Project Group (OTC Bulletin Board: PJTG) and Spectrum Sciences & Software Holdings (OTC Bulletin Board: SPSC) will webcast the following:

What: HyperDynamics Corp, NuTech Digital, Inc., The Project Group, Inc.

and Spectrum Sciences & Software Holdings Corp will present at

OTC Journal's Emerging Growth Microcap Conference.

Who: Conference Sponsors: OTC Journal and Trilogy Capital Partners.

Keynote by Dr. Richard Geist, noted author and President of The

Institute of Psychology and Investing. Introduction by Larry

Isen of the OTC Journal.

When: February 10, 2004 at 12 pm Eastern

Where: informedinvestors.com

How: Live over the Internet -- Simply log on to the web at the

address above.

Contact: Michael A. Briola at (800) 251-1770 or michael@trilogy-capital.com

If you are unable to participate during the live webcast, the call will be available for replay at informedinvestors.com.

HyperDynamics (OTC BB:HYPD) HyperDynamics, through its wholly owned subsidiary SCS Corp is exploring and developing new regions of Western Africa for energy production. SCS currently has the right to explore a 16 million acre concession off the coast of the Republic of Guinea. SCS is now processing four thousand kilometers of seismic data from the concession, and planning to drill initial test wells in late 2004. For more information, please visit www.hypd.com.



To: SEC-ond-chance who wrote (325)2/7/2004 8:49:45 AM
From: StockDung  Respond to of 544
 
Marketing Direct Concepts, Larry Isen, 702-648-6400
PR for a suspect MLM phone scam -- publicly traded stock!

216.239.41.104



To: SEC-ond-chance who wrote (325)2/24/2004 4:10:01 PM
From: StockDung  Respond to of 544
 
Celgene gains review on cancer drug

Tuesday, February 24, 2004

BY SUSAN TODD

Federal regulators yesterday agreed to review Celgene's application to market its drug Thalomid as a treatment for multiple myeloma, a form of blood cancer that affects nearly 15,000 new patients every year.

The action by the Food and Drug Administration is another step in the medical redemption of Thalomid, the new name for Thalidomide, a drug that became notorious after it was blamed for causing thousands of severe birth defects in the 1950s and 1960s in Europe and Canada.



Despite its history, Thalomid represents the heart of Celgene, a Warren Township biotechnology company focused on developing breakthrough cancer drugs. The drug was approved in the U.S. nearly six years ago as a treatment for symptoms of severe leprosy. It is marketed through a tightly regulated distribution system.

But in the past two years, the drug's unapproved use among physicians as a treatment for multiple myeloma has more than doubled. FDA approval is likely to trigger even more use.

"Oncologists are less fearful of using a drug off-label (for a use other than its regulatory approval), especially if it enhances the patient's quality of life," said Sharon di Stefano, an analyst with Sky Capital in New York City, who owns 100 shares of Celgene's stock.

"If FDA approval is given, it will open the floodgates," she said. "You will see an uptick in usage."

Once federal regulators agree to review a company's application for a medicine, it begins the clock ticking on a possible approval -- in this case, the approval would be for a supplemental use. Typically, the review process takes up to a year.

Last year, sales of Thalomid generated $200 million in revenue, making it a significant financial engine for Celgene's ongoing drug research. Multiple myeloma patients already account for about 70 percent of those sales, according to analysts at Virginia-based Friedman, Billings, Ramsey & Co.

But multiple myeloma is only the beginning of Thalomid's potential use as a cancer treatment. The company is studying the drug as a treatment for kidney and colon cancers. It is also working on another cancer drug called Revlimid, which is considered a safer, more effective version of Thalomid.

While Revlimid will be a completely different submission to the FDA, di Stefano said Thalomid's application "could help grease the skids" for the subsequent drug.

Multiple myeloma represents a small market as medicines go -- it is estimated at between $75 million to $100 million annually. But nearly 15,000 new cases of multiple myeloma are reported each year, and Thalomid represents one of the few nonintraveous medicines for its treatment, according to analysts.

"Assuming we are fortunate to get approval, Thalomid will be an important new drug to treat a deadly disease with an anticipated survival rate of two to three years," John Jackson, Celgene's chief executive, said yesterday. "This could be a big step forward for those patients."

Susan Todd can be reached at stodd@starledger.com or (973) 392-4125.

» Send This Page | » Print This Page

Copyright 2004 The Star-Ledger. Used by NJ.com with permission.



To: SEC-ond-chance who wrote (325)2/26/2004 12:07:18 PM
From: StockDung  Respond to of 544
 
Stock Hustler Ray Dirks Faces Curtain

By Matthew Goldstein
TheStreet.com Senior Writer
2/26/2004 11:09 AM EST
Click here for more stories by Matthew Goldstein

From a Nixon-era accounting blowup to postbubble stock promotion, Ray Dirks has been a central player at Wall Street's lurid fringe for decades.

But the end of the line could be approaching for the 69-year-old analyst, broker and small-cap stock specialist, whose name has even been linked to current Nasdaq bottle rocket Vaso Active (VAPH:Nasdaq - commentary - research).


Dirks, currently a managing director at Sky Capital in New York, faces an NASD enforcement action that alleges he pumped up a handful of penny stocks while working at Dirks & Co., a brokerage owned by his wife.

In a complaint filed in December, regulators contend the couple failed to tell customers that they were making a market in stocks they were simultaneously praising in their in-house research. A trial before a NASD panel on the complaint is pending. A finding against Dirks could strip him of his brokerage license and force him to forfeit any ill-gotten gains.

This isn't Dirks' first brush with the law.

In 1983, he became something of a Wall Street folk hero when he fought the Securities and Exchange Commission tooth-and-nail on an insider trading charge and won. In that battle, the SEC charged Dirks, then an insurance industry analyst, with insider trading for quietly telling some of his big brokerage clients about a massive accounting fraud at a company called Equity Funding. The Supreme Court, in a landmark 1983 decision, sided with Dirks and ruled he was only doing his job as an analyst.

More recently, regulators threatened to suspend Dirks' brokerage license last summer because he'd failed to come through with his end of a settlement in a dispute with a former customer. Now regulators are gunning for Dirks because of his equally legendary reputation for touting little-known small-cap stocks with dubious prospects.

The NASD complaint mainly focuses on reports prepared by the Dirks for four nondescript companies: DataLogic International, Carnegie Cooke, Thane International and Transmeridian Exploration. Each of the reports, all issued during the summer of 2002, carried strong buy recommendations and extravagant price targets and earnings estimates, even though all the companies were penny stocks with scant revenue.

In the case of Transmeridian, the report written by Dirks and approved by his wife Jessy set a one-year price target of $3 on the stock. At the time, shares of Transmeridian, an oil and gas concern, were selling for about 50 cents.

Yet Dirks foresaw great things for the tiny company. He predicted that revenue would soar from $5 million in 2002 to $200 million in 2004. Dirks left out that the company's auditors had expressed reservations about Transmeridian's ability to continue as a going concern.


Today, DataLogic, Carnegie Cook and Thane all trade for well under $1. Transmeridian trades for about $1.50, but its 2003 revenue will come in well under $250,000 and the company was on a pace to lose about $5 million. The company's auditors still have doubts about the company's viability.

Dirks refused to discuss the NASD action. Reached at his office at Sky Capital, he hung up the phone several times when questioned about the pending disciplinary proceeding.

Touting small stocks is nothing new for Dirks.

In the fall of 2001, soon after the Sept. 11 terror attacks and the anthrax-letter murders, Dirks threw his weight behind a small money-losing company called Vital Living Products that claimed to have developed a do-it-yourself anthrax-detection kit. Dirks arranged for the company's president to debut the life-saving product at a media event at New York's Friars Club -- which is better known for joke-telling than killing deadly germs.

In the panic-filled weeks following Sept. 11 and the Friars Club appearance, shares of Vital Living soared 4,000%, from a nickel to $2. But the euphoria quickly evaporated when agents from the Federal Bureau of Investigation arrived at the company's North Carolina headquarters with search warrants. In early 2002, Vital Living reached a settlement with the Federal Trade Commission over allegations that it "deceptively advertised" its PurTest Anthrax Test kit.

But neither the Vital Living imbroglio, nor the latest regulatory flap, seem to have slowed Dirks.

He's currently a managing director of institutional sales at Sky Capital, a three-year-old New York-based investment firm. Dirks joined Sky Capital in August 2002, a few months before Dirks & Co. officially shut its door in October of that year.


To date, Sky Capital hasn't generated much news. But the firm came close to striking gold with Vaso Active, a small-cap company that has seen its stock soar to $29, a whopping 460% increase since the company's $5-a-share offering in mid-December.

Until last October, Sky Capital was listed as the sole underwriter on the initial public offering for the money-losing company with less than $100,000. The company, however, claims to have developed a novel treatment for athlete's foot called Termin8, which uses "a revolutionary transdermal drug-delivery technology." Dirks was listed as the point man for Sky Capital on the offering in the company's September regulatory filing.

But without any explanation, Sky Capital and Dirks suddenly disappeared from Vaso Active's pre-IPO filings. In November, a new underwriter emerged to take Sky Capital's place, Kashner Davidson, a small Florida-based investment that was sanctioned by the SEC in 1996 for having an improper relationship with a stock promoter. Kashner has a history of managing IPOs for penny stocks.

Dirks won't comment on the Vaso Active stock deal, in which Kashner ultimately raised $8.3 million for the company in a $5-a-share offering. David Garbus, a lawyer for Massachusetts-based Vaso Active, also declined to comment.

Michael Recca, Sky Capital's president in New York, said the firm withdrew from the Vaso Active offering because it had some concerns about completing the deal, which would have been the firm's first initial public offering. He said Sky Capital has had no dealings with Vaso Active since it withdrew from the IPO, although he said some of the firm's customers may own shares of the pharmaceutical concern. He said it's possible that some of Dirks' customers may own shares.

Sky Capital, however, has another connection to Vaso Active. One of Vaso's directors, Gary Fromm, also is a director of Sky Capital Ventures, a subsidiary of Sky Capital. Fromm, who works out of Sky Capital's London office, could not be reached for comment.


Recca said Sky Capital has never had an equity investment in Vaso Active.

As for the NASD allegations against Dirks, Recca said the firm's attorneys are investigating them. But he noted that the NASD action concerns events that happened while Dirks was working elsewhere.

Meanwhile, trading remains brisk in shares of Vaso Active, with an average of 1 million shares changing hands each day the past two weeks.